Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | SVP, Corporate Controller | May 11, 2024 | May 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 11, 2024 · Filed May 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,081.198 |
Reported balance
After 2024-05-11 transaction · row 1
1 source rowRow 1 · 2024-05-11 · Tax withholding · Disposed 229 · Balance 17,081.198 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 20,409 |
Reported balance
Holding disclosure · report date 2024-05-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,409 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2019 Filed May 10, 2019 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 2,410 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000029 · primary_doc.xml · derivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corp. Controller (Principa 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,410 Underlying: Common Stock · 2,410 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000029 · primary_doc.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corp. Controller (Principa 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,674.9846 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| April 26, 2019 Filed Apr 26, 2019 23:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 821 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-007240 · doc4.xml · derivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 821 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2019 Filed Apr 26, 2019 23:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 821 | $175.36 | $143,970.56 |
DisclosureSEC source: 0001225208-19-007240 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,354.9846 Read SEC document |
| April 26, 2019 Filed Apr 26, 2019 23:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 821 | $42.73 | $35,077.23 |
DisclosureSEC source: 0001225208-19-007240 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,175.9846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 500 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-003457 · doc4.xml · derivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,297 Underlying: Common Stock · 500 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 500 | $175.04 | $87,519.35 |
DisclosureSEC source: 0001225208-19-003457 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,281.5648 F1 · price: This transaction was executed in multiple trades at prices ranging from $175.03 to $175.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 500 | $35.79 | $17,892.50 |
DisclosureSEC source: 0001225208-19-003457 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,781.5648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 02:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,623 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-19-003317 · doc4.xml · derivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,797 Underlying: Common Stock · 2,623 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 02:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,623 | $175.08 | $459,223.30 |
DisclosureSEC source: 0001225208-19-003317 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,281.5648 F1 · price: This transaction was executed in multiple trades at prices ranging from $175.03 to $175.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 02:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,623 | $35.79 | $93,864.06 |
DisclosureSEC source: 0001225208-19-003317 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,904.5648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2018 Filed Nov 23, 2018 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,600 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-015843 · doc4.xml · derivative · entry 6 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821 Underlying: Common Stock · 2,600 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2018 Filed Nov 23, 2018 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,600 | $153.18 | $398,273.46 |
DisclosureSEC source: 0001225208-18-015843 · doc4.xml · nonDerivative · entry 4 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,281.5648 F2 · price: This transaction was executed in multiple trades at prices ranging from $153.00 to $153.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 21, 2018 Filed Nov 23, 2018 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,600 | $42.73 | $111,085.00 |
DisclosureSEC source: 0001225208-18-015843 · doc4.xml · nonDerivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,881.5648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2018 Filed Nov 23, 2018 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,259 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-015843 · doc4.xml · derivative · entry 5 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,421 Underlying: Common Stock · 5,259 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2018 Filed Nov 23, 2018 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,259 | $153.14 | $805,384.82 |
DisclosureSEC source: 0001225208-18-015843 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,281.5648 F1 · price: This transaction was executed in multiple trades at prices ranging from $153.00 to $153.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2018 Filed Nov 23, 2018 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,259 | $42.73 | $224,690.78 |
DisclosureSEC source: 0001225208-18-015843 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,540.5648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 3,070 | $0.00 Strike: $135.83 | $0.00 |
DisclosureSEC source: 0001225208-18-009682 · doc4.xml · derivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,070 Underlying: Common Stock · 3,070 shares Expires 2025-05-16 F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 420 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009682 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,161.3091 F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 201 | $138.11 | $27,760.11 |
DisclosureSEC source: 0001225208-18-009499 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,741.3091 Read SEC document |
| May 08, 2018 Filed May 10, 2018 22:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 238 | $136.09 | $32,389.42 |
DisclosureSEC source: 0001225208-18-009118 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,942.3091 F1 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 02:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 8,120 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-18-002197 · doc4.xml · derivative · entry 6 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,120 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 02:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,657 | $130.58 | $738,708.60 |
DisclosureSEC source: 0001225208-18-002197 · doc4.xml · nonDerivative · entry 5 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,092.5514 F5 · price: This transaction was executed in multiple trades at prices ranging from $130.03 to $130.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F6 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 02:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $131.66 | $329,159.50 |
DisclosureSEC source: 0001225208-18-002197 · doc4.xml · nonDerivative · entry 4 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,749.5514 F4 · price: This transaction was executed in multiple trades at prices ranging from $131.34 to $132.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 02:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,463 | $131.47 | $323,801.50 |
DisclosureSEC source: 0001225208-18-002197 · doc4.xml · nonDerivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,249.5514 F3 · price: This transaction was executed in multiple trades at prices ranging from $131.14 to $131.8050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 02:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,400 | $130.90 | $183,265.04 |
DisclosureSEC source: 0001225208-18-002197 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,712.5514 F2 · price: This transaction was executed in multiple trades at prices ranging from $130.32 to $131.31. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 02:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,120 | $44.62 | $362,273.80 |
DisclosureSEC source: 0001225208-18-002197 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,112.5514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 322 | $110.59 | $35,609.98 |
DisclosureSEC source: 0001225208-17-009993 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,852.3757 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 4,070 | $0.00 Strike: $110.25 | $0.00 |
DisclosureSEC source: 0001225208-17-009783 · doc4.xml · derivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,070 Underlying: Common Stock · 4,070 shares Expires 2024-05-10 F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 545 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009783 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,174.3757 F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 08, 2017 Filed May 10, 2017 01:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 311 | $110.58 | $34,390.38 |
DisclosureSEC source: 0001225208-17-009438 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,629.3757 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 12,960 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-008605 · doc4.xml · derivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,960 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,960 | $109.50 | $1,419,120.00 |
DisclosureSEC source: 0001225208-17-008605 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,940.3757 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 12,960 | $25.48 | $330,220.80 |
DisclosureSEC source: 0001225208-17-008605 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,900.3757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.